CinCor Pharma, Inc. (CINC) is a clinical stage biopharmaceutical company with a novel aldosterone synthase inhibitor platform that the Company believes has “the potential to dramatically expand ...

An investigational antihypertensive agent that inhibits the enzyme involved in aldosterone production, called MLS-101, significantly reduces blood pressure in patients with uncontrolled and resistant ...

A team of medical researchers and doctors affiliated with multiple institutions in the U.S. has found, via clinical trial, that the aldosterone synthase inhibitor lorundrostat is likely safe to use ...

As the cells differentiated, they expressed even higher levels of genes involved in aldosterone synthesis and became increasingly active. "The identification of two distinct cell fates in APAs ...

Lorundrostat, a novel aldosterone synthase inhibitor, reduces blood pressure among patients with uncontrolled hypertension on at least two drugs, according to results from the phase II Target-HTN ...

Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...

Among selected people with uncontrolled hypertension, blood pressure (BP) could be successfully reduced with a highly selective aldosterone synthase inhibitor, a phase II dose-finding trial found. In ...

Lorundrostat treatment led to greater reductions in 24-hour mean blood pressure compared with placebo in trial participants with uncontrolled and treatment-resistant hypertension. Lorundrostat, a ...

Higher serum aldosterone levels among patients with chronic kidney disease (CKD) are independently associated with an increased risk for CKD progression and end-stage kidney disease (ESKD) regardless ...